DEA Schedules Insys Therapeutics’ Syndros (drona
Post# of 15624
(Total Views: 193)
Posted On: 03/23/2017 9:24:20 AM
DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug
Positive news for MMJ generally that the DEA has finally made a decision that this cannabinoid-based medicine can be moved from Schedule 1.
http://finance.yahoo.com/news/dea-schedules-i...25023.html
Positive news for MMJ generally that the DEA has finally made a decision that this cannabinoid-based medicine can be moved from Schedule 1.
http://finance.yahoo.com/news/dea-schedules-i...25023.html
(2)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼